What is the projected growth of the peripheral vascular devices market?

The market was valued at approximately USD 11.21 billion in 2024 and is projected to reach USD 18.32 billion by 2032, registering a steady CAGR of 6.43% over the forecast period. Market growth is driven by the rising prevalence of peripheral artery disease, increasing adoption of minimally invasive endovascular procedures, and continuous technological advancements in angioplasty, stent, and atherectomy devices.

What are the main drivers of demand for peripheral vascular devices?

Key demand drivers include the growing burden of peripheral artery disease, diabetes, and cardiovascular risk factors associated with aging populations. Increasing preference for minimally invasive treatments, rising procedural volumes, and improved clinical outcomes compared to open surgery are accelerating device adoption. Expansion of outpatient and ambulatory care settings further supports demand.

Which types of peripheral vascular devices are most used?

Angioplasty devices and stents account for the largest share of usage due to their widespread application in peripheral artery disease interventions. Atherectomy systems are increasingly used for treating complex and calcified lesions, while specialty catheters and embolic protection devices support procedural precision and safety across a range of endovascular procedures.

Which regions are leading the adoption of peripheral vascular devices?

North America leads the market due to advanced interventional infrastructure, high procedure volumes, and early adoption of innovative technologies. Europe shows stable growth supported by standardized clinical practices and reimbursement frameworks. Asia-Pacific is emerging as a high-growth region, driven by rising disease prevalence, healthcare infrastructure development, and expanding access to minimally invasive vascular care.

What challenges does the market face?

Major challenges include the high cost of advanced devices, procedural complexity, and dependence on skilled interventional specialists. Reimbursement variability, particularly for newer technologies, and limited access to advanced vascular care in emerging markets may constrain adoption. Device selection complexity and training requirements also add to operational challenges.

What innovations are shaping the peripheral vascular devices market?

Major innovations include drug-coated balloons, drug-eluting and covered stents, advanced atherectomy systems, bioresorbable materials, and image-guided delivery platforms. Design improvements in specialty catheters and embolic protection devices are enhancing procedural precision, safety, and outcomes in complex vascular anatomies.

What opportunities exist for investors and developers?

Opportunities exist in developing cost-effective and next-generation peripheral devices for outpatient settings, expanding product penetration in emerging markets, and addressing unmet needs in complex PAD and below-the-knee interventions. Devices that improve procedural efficiency and long-term patency offer strong commercial potential.

How can this report help understand the long-term clinical and financial benefits of investing in peripheral vascular devices?

The report demonstrates how advanced peripheral vascular devices improve blood flow restoration, reduce complication rates, shorten hospital stays, and lower overall treatment costs. These benefits support improved patient outcomes and sustainable operational efficiency for healthcare providers.

How does this report address concerns about device safety, performance, and regulatory compliance?

The report highlights adherence to regulatory frameworks such as FDA, EU MDR, and NMPA requirements, along with clinical evidence supporting device safety and effectiveness. Post-market surveillance and quality standards are also discussed to ensure consistent device performance.

How can this report help justify investment in expanding peripheral vascular device offerings?

The report identifies high-growth applications such as peripheral artery disease and minimally invasive endovascular interventions, aligning investment decisions with rising clinical demand, technological advancement, and long-term healthcare infrastructure development.

How does this report help understand technologies improving procedural efficiency?

The report outlines advances in device design, imaging compatibility, catheter technology, and delivery systems, demonstrating how these innovations reduce procedure time, enhance accuracy, and improve consistency across peripheral vascular interventions.

Peripheral Vascular Devices Market Size and Share, 2032

Q: Who are the key players in the market?

Key players include Medtronic, Abbott., Boston Scientific Corporation, TERUMO CORPORATION, BD, Cook, Cardinal Health, B. Braun SE, W. L. Gore & Associates, Inc., Getinge AB, AngioDynamics, Cordis., Merit Medical Systems, Penumbra, Inc, and, Koninklijke Philips N.V.

Market Definition

The market comprises medical devices used to diagnose and treat diseases affecting blood vessels outside the heart and brain, including peripheral arteries and veins. The market covers angioplasty balloons, stents, atherectomy systems, catheters, and embolic protection devices used in minimally invasive and surgical interventions.

These devices support vessel dilation, plaque modification, blood flow restoration, and embolic risk management during endovascular procedures. They convert procedural and imaging inputs into clinically actionable treatment outcomes, enabling effective management of peripheral artery disease, carotid artery disease, aneurysms, and related vascular conditions across hospitals, ambulatory surgical centers, and specialty clinics.

Peripheral Vascular Devices Market Overview

The global peripheral vascular devices market size was valued at USD 11.21 billion in 2024 and is projected to grow from USD 11.84 billion in 2025 to USD 18.32 billion by 2032, exhibiting a CAGR of 6.43% during the forecast period.

Market expansion is driven by the rising prevalence of peripheral artery disease, increasing adoption of minimally invasive endovascular procedures, and technological advancements in angioplasty, stent, and atherectomy devices. Expansion of outpatient care settings and ongoing improvements in vascular intervention infrastructure are further aiding this expansion.

Key Market Highlights:

The peripheral vascular devices industry size was recorded at USD 11.21 billion in 2024.
The market is projected to grow at a CAGR of 6.43% from 2025 to 2032.
North America held a share of 41.23% in 2024, valued at USD 4.62 billion.
The angioplasty devices segment garnered USD 3.83 billion in revenue in 2024.
The peripheral artery disease segment is expected to reach USD 8.70 billion by 2032.
The ambulatory surgical centers segment is anticipated to witness the fastest CAGR of 7.21% over the forecast period.
Asia Pacific is anticipated to grow at a CAGR of 6.89% through the projection period.

Major companies operating in the peripheral vascular devices market are Medtronic, Abbott., Boston Scientific Corporation, TERUMO CORPORATION, BD, Cook, Cardinal Health, B. Braun SE, W. L. Gore & Associates, Inc., Getinge AB, AngioDynamics, Cordis., Merit Medical Systems, Penumbra, Inc, and Koninklijke Philips N.V.

Market growth is driven by the increasing need for improved device performance in complex peripheral vascular interventions to support effective clinical decision-making. Rising procedural complexity in peripheral artery disease is highlighting the clinical importance of combining precise lesion access with reliable catheter deliverability and control to guide targeted endovascular treatment.

Healthcare providers are adopting advanced and specialty peripheral catheters that integrate hydrophilic coatings, enhanced torque response, and low-profile designs to reduce procedural variability, shorten intervention times, and improve procedural confidence.

Leading manufacturers are strengthening their peripheral catheter portfolios through design and material innovations that improve usability and workflow efficiency, supporting broader adoption across hospital and outpatient endovascular settings.

For instance, in September 2024, B. Braun Medical Inc. received the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Introcan Safety 2 Deep Access IV Catheter, expanding its Introcan Safety 2 catheter portfolio and reinforcing its focus on enhanced vascular access safety and performance.

What factors are driving demand for peripheral vascular devices in the treatment of vascular disorders?

The rising prevalence of peripheral artery disease and other vascular disorders, driven by increasing rates of diabetes, obesity, hypertension, smoking, and an aging population, is boosting demand for peripheral vascular devices.

Growing incidence of arterial occlusions, aneurysms, and venous complications is underscoring the need for angioplasty balloons, stents, and atherectomy systems to restore blood flow and reduce procedural risks. Improving disease awareness, earlier diagnosis, and the growing adoption of minimally invasive endovascular treatments are further supporting market growth.

According to the U.S. Centers for Disease Control and Prevention (CDC), peripheral artery disease affects approximately 6.5 million adults aged 40 years and older in the U.S., with prevalence increasing significantly among individuals aged 60+, diabetics, and those with a history of smoking.

What strategies are manufacturers adopting to overcome high costs and procedural complexity in peripheral vascular interventions?

A key challenge restraining the growth of the peripheral vascular devices market is the high cost and procedural complexity associated with advanced endovascular interventions. Adoption of next-generation stents, atherectomy systems, imaging-guided devices, and specialty catheters requires significant capital investment, specialized infrastructure, and highly trained interventional specialists.

Additionally, procedural variability, reimbursement limitations, and device selection complexity increase operational burden for healthcare providers. These factors limit adoption among smaller hospitals, ambulatory surgical centers, and healthcare systems in cost-sensitive and emerging markets.

To address this challenge, market participants are focusing on device miniaturization, simplified delivery systems, and integrated platform designs that reduce procedural complexity. Manufacturers are also expanding physician training programs, clinical education initiatives, and partnerships with healthcare providers to improve procedural efficiency, support skill development, and enable broader adoption of peripheral vascular devices across diverse care settings.

How are next-generation peripheral vascular devices transforming outcomes and safety in minimally invasive vascular procedures?

A key trend influencing the peripheral vascular devices market is ongoing innovation in product design to improve procedural accuracy and patient safety. Healthcare providers are increasingly adopting next-generation stents, drug-coated balloons, atherectomy systems, and EVAR technologies that incorporate advanced materials, specialized surface coatings, and image-guided delivery mechanisms.

These advancements improve device performance, durability, and deployment precision in minimally invasive interventions. Integrating technologically advanced peripheral vascular devices into routine endovascular workflows improves clinical outcomes, reduces complication rates, and supports consistent treatment results, boosting adoption across hospital and outpatient care settings and supporting sustained market expansion.

In September 2024, Argon Medical Devices launched the CLEANER Vac Thrombectomy System, designed for removing blood clots from the peripheral venous vasculature. The initiative aims to address the growing demand for effective minimally invasive solutions in venous thromboembolic interventions.

Peripheral Vascular Devices Market Report Snapshot

Segmentation	Details
By Product Type	Angioplasty Devices, Stents, Atherectomy Devices, Embolic Protection Devices, Catheters, Others
By Application	Peripheral Artery Disease (PAD), Carotid Artery Disease, Renal Artery Disease, Abdominal Aortic Aneurysm, Others
By End User	Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation

By Product Type (Angioplasty Devices, Stents, Atherectomy Devices, Embolic Protection Devices, Catheters, and Others): The angioplasty devices segment earned USD 3.83 billion in 2024, mainly due to high peripheral artery disease procedure volumes and the widespread adoption of drug-coated balloons to reduce restenosis and improve long-term outcomes.
By Application (Peripheral Artery Disease (PAD), Carotid Artery Disease, Renal Artery Disease, Abdominal Aortic Aneurysm, and Others): The peripheral artery disease segment held a share of 45.32% in 2024, fueled by the high prevalence of PAD globally and the frequent need for repeat endovascular interventions using angioplasty, stenting, and atherectomy devices.
By End User (Hospitals, Ambulatory Surgical Centers (ASCs), and Specialty Clinics): The hospitals segment is projected to reach USD 10.63 billion by 2032, attributed to a high volume of complex peripheral vascular procedures, advanced interventional infrastructure, and specialized vascular care teams

What is the market scenario in North America and Asia-Pacific region?

Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America peripheral vascular devices market share stood at 41.23% in 2024, with a valuation of USD 4.62 billion. This dominance is reinforced by a high prevalence of peripheral artery disease, well-established interventional infrastructure, and strong adoption of advanced endovascular technologies.

The U.S. leads regional demand, propelled by an aging population, a high burden of diabetes and cardiovascular risk factors, and broad access to minimally invasive treatments. Favorable reimbursement coverage for peripheral interventions and early adoption of drug-coated balloons, atherectomy systems, and advanced catheter technologies further support domestic market growth.

In December 2024, Terumo Interventional Systems, a division of Terumo Corporation, launched the R2P NaviCross peripheral support catheter in the U.S., expanding its radial-to-peripheral (R2P) product portfolio. The 200 cm catheter features a double-braided stainless-steel construction designed to enhance trackability and torque control for complex peripheral vascular interventions.

The Asia-Pacific peripheral vascular devices industry is set to grow at a CAGR of 6.89% over the forecast period. This rapid growth is propelled by an expanding patient population and improving access to interventional vascular care.

Rising prevalence of peripheral artery disease, diabetes, and lifestyle-related cardiovascular risk factors is increasing demand for peripheral interventions across major economies such as China, India, and Japan. Ongoing investments in hospital infrastructure, expansion of catheterization laboratories, and growing adoption of minimally invasive endovascular procedures are further supporting regional market expansion.

For instance, in February 2025, Shanghai Tendfo Medical Device Co., Ltd. received approval from the China National Medical Products Administration (NMPA) for its Tendvia Pulmonary Artery Thrombectomy System. The device is indicated for transcatheter thrombectomy in patients with acute high-risk or intermediate-risk pulmonary embolism, offering a minimally invasive option for critically ill patients.

Regulatory Frameworks

In the U.S., peripheral vascular devices are regulated by the U.S. Food and Drug Administration (FDA) under medical device regulations. Products such as angioplasty balloons, stents, atherectomy systems, and embolic protection devices require 510(k) clearance or Premarket Approval (PMA), depending on risk classification. The FDA evaluates these devices for safety, performance, clinical effectiveness, and manufacturing quality before market authorization.
In the European Union, peripheral vascular devices are governed under the Medical Device Regulation (MDR), which imposes stricter requirements for clinical evidence, risk management, and post-market surveillance compared to the former MDD framework.
Across the Asia-Pacific region, China regulates peripheral vascular devices through the National Medical Products Administration (NMPA), emphasizing local clinical evaluation, product testing, and quality compliance.
Globally, organizations such as the International Medical Device Regulators Forum (IMDRF) promote regulatory harmonization, convergence of safety standards, and best practices for medical device evaluation. These efforts facilitate international market access and improve post-market surveillance for peripheral vascular devices worldwide.

Competitive Landscape

Leading players operating in the peripheral vascular devices industry are focusing on technological innovation, portfolio expansion, and procedural efficiency to strengthen their competitive position. Major manufacturers are investing in next-generation stents, drug-coated balloons, atherectomy systems, and specialty catheters to improve deliverability, durability, and clinical outcomes in complex peripheral interventions.

Companies are increasingly integrating imaging compatibility, enhanced coatings, and advanced materials into device design to support minimally invasive procedures and reduce complication rates.

In March 2025, Boston Scientific introduced an enhanced FilterWire EZ embolic protection system in select European markets. The updated system incorporates a guidewire with a 110-micron pore filter at the distal tip, designed to capture embolic debris while preserving blood flow and ensuring consistent vessel wall apposition during peripheral vascular interventions.

Key Companies in Peripheral Vascular Devices Market:

Medtronic
Abbott
Boston Scientific Corporation
TERUMO CORPORATION
BD
Cook
Cardinal Health
Braun SE
L. Gore & Associates, Inc.
Getinge AB
AngioDynamics
Cordis
Merit Medical Systems
Penumbra, Inc
Koninklijke Philips N.V.

Recent Developments

In July 2025, MicroPort Endovastec reported the first commercial use of its Talos Thoracic Stent Graft System in Argentina to treat a Stanford type B aortic dissection. The procedure employed a single, personalized stent graft to restore blood flow while reducing the risk of spinal cord ischemia.
In April 2024, the U.S. Food and Drug Administration (FDA) approved Abbott’s Esprit BTK System, which features an Enviroximes-eluting resorbable scaffold. The system is designed for the treatment of chronic limb-threatening ischemia affecting below-the-knee vessels, expanding minimally invasive treatment options for complex peripheral artery disease cases.

Peripheral Vascular Devices Market